Loxoprofen prevents EGFR-TKI-related skin rash in non-small cell lung cancer patients: a single-center retrospective study

Loxoprofen prevents EGFR-TKI-related skin rash in non-small cell lung cancer patients: a single-center retrospective study - Loxoprofen prevents EGFR-TKI-related skin rash in non-small cell lung cancer patients: a single-center retrospective study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030657

Enrollment

Registered

2018-01-01

Start date

2016-06-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who had histologically confirmed NSCLC at International University of Health and Welfare Ichikawa Hospital from October 2011 to March 2017. The patients who commenced EGFR-TKI treatment in our hospital, over 37 years old, and whose pathologically confirmed NSCLC stage was 2 to 4 were considered eligible to include our study.

Exclusion criteria

Exclusion criteria: Patient who received EGFR-TKIs for within 3 monthswere excluded.

Design outcomes

Primary

Measure	Time frame
The incidence of EGFR-TKIs related skin rash	—

Countries

Japan

Contacts

Public ContactYOHEI IIMURA

International University of Health and Welfare Ichikawa Hospital Department of Pharmacy

yo.0519.hei@gmail.com0473751111

Outcome results